CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma Meeting Abstract
| Authors: | Sangro, B.; Park, J.; Finn, R.; Cheng, A.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K.; Harding, J.; Merle, P.; Rosmorduc, O.; Wyrwicz, L.; Schott, E.; Choo, S.; Kelley, R.; Begic, D.; Chen, G.; Neely, J.; Tschaika, M.; Yau, T. |
| Abstract Title: | CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma |
| Meeting Title: | ESMO 22nd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Jul 1-4 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-07-01 |
| Start Page: | S241 |
| End Page: | S242 |
| Language: | English |
| ACCESSION: | WOS:000558722000448 |
| DOI: | 10.1016/j.annonc.2020.04.078 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA-3 -- Source: Wos |
